UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Heerfordt's Syndrome Associated with Trigeminal Nerve Palsy and Reversed Halo Sign

Internal Medicine, 2021/06/01, Vol.60(11), pp.1747-1752

2021

Link zum Volltext

Verfügbarkeit prüfen

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

Internal Medicine, 2021/12/15, Vol.60(24), pp.3941-3945

2021

Link zum Volltext

Verfügbarkeit prüfen

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Internal Medicine, 2019/04/01, Vol.58(7), pp.985-989

2019

Link zum Volltext

Verfügbarkeit prüfen

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

Internal Medicine, 2020/07/15, Vol.59(14), pp.1739-1740

2020

Link zum Volltext

Verfügbarkeit prüfen

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review

Internal Medicine, 2020/03/15, Vol.59(6), pp.823-828

2020

Link zum Volltext

Verfügbarkeit prüfen

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation

Internal Medicine, 2020/09/01, Vol.59(17), pp.2161-2164

2020

Link zum Volltext

Verfügbarkeit prüfen

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages

Internal Medicine, 2019/10/15, Vol.58(20), pp.3033-3037

2019

Link zum Volltext

Verfügbarkeit prüfen

Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies

Acta medica Okayama, 2020-10, Vol.74 (5), p.371-379

2020

Link zum Volltext

Verfügbarkeit prüfen

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

Internal Medicine, 2019/06/01, Vol.58(11), pp.1625-1627

2019

Link zum Volltext

Verfügbarkeit prüfen

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Japanese journal of clinical oncology, 2019-05, Vol.49 (5), p.458-464

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK ‐rearranged non‐small cell lung cancer

Cancer science, 2023-11, Vol.114 (11), p.4343-4354

2023

Link zum Volltext

Verfügbarkeit prüfen

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Scientific reports, 2018-01, Vol.8 (1), p.1955-11, Article 1955

2018

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia

Respiratory medicine case reports, 2022-01, Vol.37, p.101662, Article 101662

2022

Link zum Volltext

Verfügbarkeit prüfen

Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations

Biochemical and biophysical research communications, 2020-11, Vol.532 (3), p.341-346

2020

Link zum Volltext

Verfügbarkeit prüfen

A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing

Internal Medicine, 2024, pp.2938-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Identification of targetable kinases in idiopathic pulmonary fibrosis

Respiratory research, 2022-02, Vol.23 (1), p.20-20, Article 20

2022

Link zum Volltext

Verfügbarkeit prüfen

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Journal of cancer research and clinical oncology, 2022-08, Vol.148 (8), p.1869-1877

2022

Link zum Volltext

Verfügbarkeit prüfen

Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

Respiratory investigation, 2019-07, Vol.57 (4), p.330-336

2019

Link zum Volltext

Verfügbarkeit prüfen

A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R

Japanese journal of clinical oncology, 2021-05, Vol.51 (6), p.956-965

2021

Link zum Volltext

Verfügbarkeit prüfen

Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report

Internal medicine (Tokyo, 1992), , Article 2429-23

Link zum Volltext

Verfügbarkeit prüfen

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

Case reports in oncology, 2021-01, Vol.14 (1), p.197-201

2021

Link zum Volltext

Verfügbarkeit prüfen

EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice

Lung cancer (Amsterdam, Netherlands), 2019-10, Vol.136, p.86-93

2019

Link zum Volltext

Verfügbarkeit prüfen

Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report

Thoracic cancer, 2021-06, Vol.12 (11), p.1770-1774

2021

Link zum Volltext

Verfügbarkeit prüfen

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an EGFR Mutation With a History of Acquired Resistance to Osimertinib

Internal Medicine, 2019, pp.2152-18

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(83)
Berichte
(14)

Sprache

Englisch
(92)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(52)
Life Sciences & Biomedicine
(51)
Oncology
(26)
Lung Cancer
(24)
Humans
(23)
Case Report
(19)
Female
(16)
Mutation
(16)
Lung Neoplasms - Drug Therapy
(15)
Respiratory System
(14)
Epidermal Growth Factor
(13)
Tumors
(12)
Non-Small Cell Lung Carcinoma
(11)
Aged
(10)
Chemotherapy
(10)
Epidermal Growth Factor Receptors
(10)
Non-Small Cell Lung Cancer
(10)
Osimertinib
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Case Reports
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Heerfordt's Syndrome Associated with Trigeminal Nerve Palsy and Reversed Halo Sign

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review

Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages

Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK ‐rearranged non‐small cell lung cancer

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia

Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations

A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing

Identification of targetable kinases in idiopathic pulmonary fibrosis

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R

Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report

EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice

Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an EGFR Mutation With a History of Acquired Resistance to Osimertinib

Suchergebnisse filtern